# A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

> **NCT04696432** · PHASE1 · COMPLETED · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 7 (actual)

## Conditions studied

- Non-Hodgkin's B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** Prizloncabtagene autoleucel

## Key facts

- **NCT ID:** NCT04696432
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-27
- **Primary completion:** 2023-07-31
- **Final completion:** 2023-12-30
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04696432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04696432, "A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04696432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*